These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

296 related articles for article (PubMed ID: 26850066)

  • 21. Prevalence of Plasmodium falciparum transmission reducing immunity among primary school children in a malaria moderate transmission region in Zimbabwe.
    Paul NH; Vengesai A; Mduluza T; Chipeta J; Midzi N; Bansal GP; Kumar N
    Acta Trop; 2016 Nov; 163():103-8. PubMed ID: 27491342
    [TBL] [Abstract][Full Text] [Related]  

  • 22. KILchip v1.0: A Novel
    Kamuyu G; Tuju J; Kimathi R; Mwai K; Mburu J; Kibinge N; Chong Kwan M; Hawkings S; Yaa R; Chepsat E; Njunge JM; Chege T; Guleid F; Rosenkranz M; Kariuki CK; Frank R; Kinyanjui SM; Murungi LM; Bejon P; Färnert A; Tetteh KKA; Beeson JG; Conway DJ; Marsh K; Rayner JC; Osier FHA
    Front Immunol; 2018; 9():2866. PubMed ID: 30619257
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antibody profiles to wheat germ cell-free system synthesized Plasmodium falciparum proteins correlate with protection from symptomatic malaria in Uganda.
    Kanoi BN; Takashima E; Morita M; White MT; Palacpac NM; Ntege EH; Balikagala B; Yeka A; Egwang TG; Horii T; Tsuboi T
    Vaccine; 2017 Feb; 35(6):873-881. PubMed ID: 28089547
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phase I Clinical Trial of a Recombinant Blood Stage Vaccine Candidate for Plasmodium falciparum Malaria Based on MSP1 and EBA175.
    Chitnis CE; Mukherjee P; Mehta S; Yazdani SS; Dhawan S; Shakri AR; Bhardwaj R; Gupta PK; Hans D; Mazumdar S; Singh B; Kumar S; Pandey G; Parulekar V; Imbault N; Shivyogi P; Godbole G; Mohan K; Leroy O; Singh K; Chauhan VS
    PLoS One; 2015; 10(4):e0117820. PubMed ID: 25927360
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The quantity and quality of African children's IgG responses to merozoite surface antigens reflect protection against Plasmodium falciparum malaria.
    Courtin D; Oesterholt M; Huismans H; Kusi K; Milet J; Badaut C; Gaye O; Roeffen W; Remarque EJ; Sauerwein R; Garcia A; Luty AJ
    PLoS One; 2009 Oct; 4(10):e7590. PubMed ID: 19859562
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evaluation of the safety and immunogenicity of Plasmodium falciparum apical membrane antigen 1, merozoite surface protein 1 or RTS,S vaccines with adjuvant system AS02A administered alone or concurrently in rhesus monkeys.
    Pichyangkul S; Tongtawe P; Kum-Arb U; Yongvanitchit K; Gettayacamin M; Hollingdale MR; Limsalakpetch A; Stewart VA; Lanar DE; Dutta S; Angov E; Ware LA; Bergmann-Leitner ES; House B; Voss G; Dubois MC; Cohen JD; Fukuda MM; Heppner DG; Miller RS
    Vaccine; 2009 Dec; 28(2):452-62. PubMed ID: 19857448
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Development of a high-throughput flexible quantitative suspension array assay for IgG against multiple Plasmodium falciparum antigens.
    Ubillos I; Campo JJ; Jiménez A; Dobaño C
    Malar J; 2018 May; 17(1):216. PubMed ID: 29843713
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cellular responses to modified Plasmodium falciparum MSP119 antigens in individuals previously exposed to natural malaria infection.
    Okafor CM; Anumudu CI; Omosun YO; Uthaipibull C; Ayede I; Awobode HO; Odaibo AB; Langhorne J; Holder AA; Nwuba RI; Troye-Blomberg M
    Malar J; 2009 Nov; 8():263. PubMed ID: 19930613
    [TBL] [Abstract][Full Text] [Related]  

  • 29. New antigens for a multicomponent blood-stage malaria vaccine.
    Osier FH; Mackinnon MJ; Crosnier C; Fegan G; Kamuyu G; Wanaguru M; Ogada E; McDade B; Rayner JC; Wright GJ; Marsh K
    Sci Transl Med; 2014 Jul; 6(247):247ra102. PubMed ID: 25080477
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Functional Antibodies and Protection against Blood-stage Malaria.
    Teo A; Feng G; Brown GV; Beeson JG; Rogerson SJ
    Trends Parasitol; 2016 Nov; 32(11):887-898. PubMed ID: 27546781
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Plasmodium falciparum malaria in children aged 0-2 years: the role of foetal haemoglobin and maternal antibodies to two asexual malaria vaccine candidates (MSP3 and GLURP).
    Kangoye DT; Nebie I; Yaro JB; Debe S; Traore S; Ouedraogo O; Sanou G; Soulama I; Diarra A; Tiono A; Marsh K; Sirima SB; Bejon P
    PLoS One; 2014; 9(9):e107965. PubMed ID: 25238160
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Soluble antigens of intra-erythrocyte stages of Plasmodium falciparum: diagnostic and vaccinal value].
    Cruz Cubas AB; Gentilini M; Danis M; Monjour L
    Pathol Biol (Paris); 1993 May; 41(5):495-9. PubMed ID: 8414684
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immunological responses against Plasmodium falciparum Apical Membrane Antigen 1 vaccines vary depending on the population immunized.
    Miura K; Zhou H; Diouf A; Tullo G; Moretz SE; Aebig JA; Fay MP; Miller LH; Doumbo OK; Sagara I; Dicko A; Long CA; Ellis RD
    Vaccine; 2011 Mar; 29(12):2255-61. PubMed ID: 21277408
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Breadth of Functional Antibodies Is Associated With Plasmodium falciparum Merozoite Phagocytosis and Protection Against Febrile Malaria.
    Kana IH; Singh SK; Garcia-Senosiain A; Dodoo D; Singh S; Adu B; Theisen M
    J Infect Dis; 2019 Jun; 220(2):275-284. PubMed ID: 30820557
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Strain-transcending immune response generated by chimeras of the malaria vaccine candidate merozoite surface protein 2.
    Krishnarjuna B; Andrew D; MacRaild CA; Morales RA; Beeson JG; Anders RF; Richards JS; Norton RS
    Sci Rep; 2016 Feb; 6():20613. PubMed ID: 26865062
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Naturally acquired antibody response to a Plasmodium falciparum chimeric vaccine candidate GMZ2.6c and its components (MSP-3, GLURP, and Pfs48/45) in individuals living in Brazilian malaria-endemic areas.
    Baptista BO; de Souza ABL; Riccio EKP; Bianco-Junior C; Totino PRR; Martins da Silva JH; Theisen M; Singh SK; Amoah LE; Ribeiro-Alves M; Souza RM; Lima-Junior JC; Daniel-Ribeiro CT; Pratt-Riccio LR
    Malar J; 2022 Jan; 21(1):6. PubMed ID: 34983540
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Development of vaccines against Plasmodium falciparum malaria: taking lessons from naturally acquired protective immunity.
    Hviid L
    Microbes Infect; 2007 May; 9(6):772-6. PubMed ID: 17398137
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immunogenicity of a recombinant malaria vaccine candidate, domain I+II of AMA-1 ectodomain, from Indian P. falciparum alleles.
    Lalitha PV; Biswas S; Pillai CR; Saxena RK
    Vaccine; 2008 Aug; 26(35):4526-35. PubMed ID: 18590786
    [TBL] [Abstract][Full Text] [Related]  

  • 39. IgG2 antibodies against a clinical grade Plasmodium falciparum CSP vaccine antigen associate with protection against transgenic sporozoite challenge in mice.
    Schwenk R; DeBot M; Porter M; Nikki J; Rein L; Spaccapelo R; Crisanti A; Wightman PD; Ockenhouse CF; Dutta S
    PLoS One; 2014; 9(10):e111020. PubMed ID: 25343487
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Within-population genetic diversity of Plasmodium falciparum vaccine candidate antigens reveals geographic distance from a Central sub-Saharan African origin.
    Tanabe K; Mita T; Palacpac NM; Arisue N; Tougan T; Kawai S; Jombart T; Kobayashi F; Horii T
    Vaccine; 2013 Feb; 31(9):1334-9. PubMed ID: 23295064
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.